13.11.2007 21:10:00
|
Accelrys to Offer Free Version of its Scientific Operating Platform to Academic Researchers
Accelrys, Inc. (NASDAQ:ACCL), a leading provider of scientific business
intelligence solutions, announced the release of SciTegic Pipeline Pilot™
Student Edition software, a free stand-alone version of its scientific
operating platform. SciTegic Pipeline Pilot Student Edition will enable
academic researchers to create scientific software applications,
integrate their scientific code and share their innovations within the
academic community and with the commercial scientific community.
Accelrys will host a free library on its community web site to promote
the sharing of scientific innovation between academia and industry.
The Student Edition comes with free component collections for
statistics, reporting, and data and application integration. Academics
can also select from Accelrys’ scientific
collections in chemistry, sequence analysis, and gene expression to
support specific research efforts.
"The broad availability of SciTegic Pipeline
Pilot Student Edition will foster scientific exchange and collaboration.
Commercial users of SciTegic Pipeline Pilot will get convenient access
to an unparalleled amount of cutting edge science from academic
researchers,” said Mark Emkjer, President and
Chief Executive Officer of Accelrys.
"Accelrys' release of SciTegic Pipeline Pilot
Student Edition is great news for drug discovery in academia and
industry. Universities can now benefit from the industry standard
workflow tool and industry can gain from the sharing of innovative new
protocols from academia. An interoperable informatics platform is
exactly what is needed if we want to share knowledge and improve everyone’s
drug discovery productivity,” said Professor
Andrew Hopkins, FRSC (formally with Pfizer), Scottish Universities Life
Sciences Alliance Professor of Translational Biology and Chair of
Chemical Informatics, University of Dundee, Scotland, UK.
"The release of SciTegic Pipeline Pilot Student Edition to the academic
community will be a boon for cheminformatics and bioinformatics
research. Accelrys’ scientific operating
platform has revolutionized the way that scientific computing gets done
in the pharmaceutical industry, and I believe it can have a similar
effect in academia. I hope this move will spur a new wave of innovation,
enabling research that uses tools from different domains and disciplines
and encouraging academic researchers to publish their code as web
services," said David Wild, Assistant Professor and Associate Director
of Cheminformatics, Indiana University.
SciTegic Pipeline Pilot is used by over 300 companies worldwide to
streamline the integration and analysis of the vast quantities of data
flooding the research and development informatics world. The software
allows researchers to graphically compose data processing workflows,
known as protocols, using hundreds of different configurable components
for operations such as data retrieval and manipulation, property
calculations, computational filtering, and reporting. Integrated
technologies are also available from over 30 third-party software
companies that are members of the Accelrys Independent Software Vendor
program, giving SciTegic Pipeline Pilot users access to a wide array of
additional tools.
For more information and terms and conditions for SciTegic Pipeline
Pilot Student Edition, please visit http://www.accelrys.com/products/scitegic/pp-student/index.html
today.
About Accelrys, Inc.
Accelrys develops and commercializes scientific business intelligence
software for the integration, mining, analysis, modeling and simulation,
management and interactive reporting of scientific data. Our solutions
are used by biologists, chemists, materials scientists, and information
technology professionals for product design as well as drug discovery
and development. Our technology and services are designed to meet the
needs of today’s leading research and
development organizations including leading commercial, government and
academic organizations. Many of the largest pharmaceutical,
biotechnology, chemical, and petroleum companies worldwide use our
solutions. Accelrys is headquartered in San Diego, California. For more
information about Accelrys, visit its website at http://www.accelrys.com/ Forward-Looking Statements
This press release contains forward-looking statements. Such statements,
including statements relating to SciTegic Pipeline Pilot Student
Edition, including its features and potential demand therefore, are
subject to risks and uncertainties including, but not limited to, the
risks that SciTegic Pipeline Pilot Student Edition will not successfully
include all features described herein or demand relating to SciTegic
Pipeline Pilot Student Edition, and potential resulting decrease in
demand and revenue from the academic community for the commercial
version, and other risks and uncertainties described in documents
Accelrys has filed with the Securities and Exchange Commission,
including its most recent report on Form 10-K and any subsequent interim
filings. All forward-looking statements in this document are qualified
entirely by the cautionary statements included in this document and such
filings. These risks and uncertainties could cause actual results to
differ materially from results expressed or implied by forward-looking
statements contained in this document. These forward-looking statements
speak only as of the date of this document. Accelrys disclaims any
intent or obligation to publicly update or revise any forward-looking
statements contained herein to reflect any change in its expectations
with regard thereto or any change in events, conditions or circumstances
on which any such statement is based.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Accelrys Inc Cash Settlement At USD 12.50 A Shmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Accelrys Inc Cash Settlement At USD 12.50 A Shmehr Analysen
Indizes in diesem Artikel
NASDAQ Comp. | 19 478,88 | -0,06% |